A guanosine analogue antiviral agent used for the treatment of various herpesvirus (HSV) infections.

A HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.

A HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.

A herbicide agent. .

A herbicide safener for gramineous crops..

SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker u

A heterobifunctional cross-linking reagent incorporating an extended spacer with amine and sulfhydryl reactivity.

A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.

A high affinity, selective inhibitor of Rho family GTPases with EC50 of 16-120 uM.

A high-affinity, allosteric HIV-1 and HIV-2 reverse transcriptase inhibitor (NNRTI) with EC50 of 1 nM.

A high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM.

A highly potent agonist of σ1 receptor with Ki of 0.8 nM.

A highly potent and competitive S-adenosylhomocysteine hydrolase inhibitor with Ki of 0.05 nM, also inhibits histone methyltransferase EZH2.

A highly potent and selective antagonist of the platelet P2Y1 receptor with Ki of 0.78 nM.

A highly potent and selective antagonist of the platelet P2Y1 receptor with Ki of 0.78 nM.

A highly potent and selective dual FAAH/MAGL inhibitor with IC50 of 1-3 nM against FAAH, inhibits mouse (IC50=410 nM) and human (IC50=1.4 uM) MAGL.

A highly potent and selective GRK2 inhibitor with IC50 of 18 nM.

A highly potent and selective inhibitor of CBP/p300 bromodomain with Kd of 0.23/0.47 uM respectively, with high selectivity over all other BD families, including the BET family.

A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH)..

A highly potent and selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) in development for the treatment of nonalcoholic steatohepatitis (NASH)..

A highly potent and selective inhibitor of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.

A highly potent and selective kappa Opioid receptor (KOR) antagonist with Ki of 0.3 nM.